Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
|Articles|November 6, 2020
How one OD incorporates new contact lens technology in his practice
Author(s)David Kading, OD, FAAO, FCLSA
Will new contact lens technology bring about better patient care?
Advertisement
· Is this lens going to serve a purpose other than a lens I currently have?
· If so, is it a better technology and is it going to bring about better patient care?
Advertisement
Related to this article
Maria Sampalis, OD, tells Diana Canto-Sims, OD, in this week's episode that the biggest impact AI has made at her practice is when used in the exam room as a scribe for routine patients.
An independent analysis of 600 patients across 20 US optometry offices found contact lens wearers generate 29% to 86% higher annual profits than eyeglasses-only patients.
Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.
Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.
Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.
To kick off Perimenopause and Menopause Awareness Month, Meredith Bishop, OD, MS, FAAO, gives an overview of her poster "Perceptions of Linking Presbyopia with Perimenopause: A Survey of US Female Eye Care Professionals."
Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis
2
AAOpt 2026: Aflibercept 8 mg extends RVO dosing as Amsler misses AMD damage
3
AAOpt 2026: The real-world impact of treatment switch to latanoprostene bunod
4
AAOpt 2026: Patient-reported blurred vision improvement with Vevye
5